Exact Sciences (EXAS) Q4 Revenue Tops Consensus

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($2.79), may not compare to the analyst estimate of ($0.22). Revenue for the quarter came in at $466.3 million versus the consensus estimate of $446.22 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c